Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein

Author(s): Tertov VV, Kaplun VV, Sobenin IA, Boytsova EY, Bovin NV, et al.

Abstract

In earlier studies we have found that incubation of low density lipoprotein (LDL) with autologous blood plasma-derived serum leads to a loss of sialic acid from lipoprotein particles. In this study we demonstrated that sialic acid removed from LDL was transferred to glycoconjugates of lipoproteins, glycoproteins and sphingolipids of human serum. This showed that human serum contained the trans-sialidase activity. Gel-filtration chromatography of human blood serum demonstrated the presence of trans-sialidase activity in lipoprotein subfractions as well as in lipoprotein-deficient serum. Trans-sialidase (about 65 kDa) was isolated from lipoprotein-deficient serum using affinity chromatography carried out with Neu5Acalpha2-8Neu5Ac-sepharose FF-6. Optimal pH values for the trans-sialidase were 3.0, 5.0 and 7.0. Calcium and magnesium ions stimulated the enzyme activity at millimolar concentrations. Isolated enzyme can remove sialic acid from LDL, IDL, VLDL, and HDL particles (in decreasing rate order). Serum trans-sialidase transferred sialic acid from glycoconjugates of plasma proteins (fetuin, transferrin) and gangliosides (GM3, GD3, GM1, GD1a, GD1b). Sialylated glycoconjugates of human blood erythrocytes also served as substrate for serum trans-sialidase. We have found that sialic acid can also be removed from N- and O-linked glycans, sialylated Le(x) and Le(a), oligosialic acids, and sphingolipid carbohydrate chains. The rate of sialic acid release decreased in the following order: alpha2,6>alpha2,3>>alpha2,8. Transferred molecule of sialic acid can form alpha2,6, alpha2,3 and to a lesser degree alpha2,8 linkage with galactose, N-acetyl-galactosamine or sialic acid of acceptors. The glycoconjugates of erythrocytes, lipoprotein particles, plasma proteins, neutral sphingolipids and gangliosides may serve as acceptors of transferred sialic acid. Trans-sialidase-treated native LDL becomes desialylated and then can induce cholesteryl ester accumulation in human aortic intimal smooth muscle cells. Thus, trans-sialidase may be involved in the early stages of atherogenesis characterized by foam cell formation.

Similar Articles

LDL cholesterol: the lower the better

Author(s): Martin SS, Blumenthal RS, Miller M

High density lipoproteins and atherosclerosis: emerging aspects

Author(s): Sala F, Catapano AL, Norata GD

High-density lipoprotein function, dysfunction, and reverse cholesterol transport

Author(s): Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD

Targeting Innate Immunity for CV Benefit

Author(s): Moore KJ, Freeman MW

Blood serum atherogenicity associated with coronary atherosclerosis

Author(s): Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IYu, Martsenyuk ON, et al.

Characteristics of low density lipoprotein isolated from circulating immune complexes

Author(s): Tertov VV, Sobenin IA, Orekhov AN, Jaakkola O, Solakivi T, et al.

Presence of a modified low density lipoprotein in humans

Author(s): Avogaro P, Bon GB, Cazzolato G

Autoantibodies against modified low density lipoprotein

Author(s): Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, et al.

Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis

Author(s): Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, et al.

Lipoprotein immune complexes as markers of atherosclerosis

Author(s): Orekhov AN, Kalenich OS, Tertov VV, Novikov ID

Diagnostic value of immune cholesterol as a marker for atherosclerosis

Author(s): Orekhov AN, Kalenich OS, Tertov VV, Perova NV, Novikov IyD, et al.

Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis

Author(s): Sobenin IA, Karagodin VP, Melnichenko AC, Bobryshev YV, Orekhov AN

Pluronic block copolymers inhibit low density lipoprotein self-association

Author(s): Melnichenko AA, Aksenov DV, Myasoedova VA, Panasenko OM, Yaroslavov AA, et al.

Three-dimensional cytoarchitecture of normal and atherosclerotic intima of human aorta

Author(s): Rekhter MD, Andreeva ER, Mironov AA, Orekhov AN

Primary cultures of enzyme-isolated cells from normal and atherosclerotic human aorta

Author(s): Orekhov AN, Andreeva ER, Krushinsky AV, Smirnov VN

Lipids in cells of atherosclerotic and uninvolved human aorta

Author(s): Orekhov AN, Tertov VV, Novikov ID, Krushinsky AV, Andreeva ER, et al.

Adult human aortic cells in primary culture: heterogeneity in shape

Author(s): Orekhov AN, Krushinsky AV, Andreeva ER, Repin VS, Smirnov VN

Cell proliferation in normal and atherosclerotic human aorta

Author(s): Orekhov AN, Kosykh VA, Repin VS, Smirnov VN

Primary culture of human aortic intima cells as a model for testing anti-atherosclerotic drugs

Author(s): Orekhov AN, Tertov VV, Kudryashov SA, Khashimov KhA, Smirnov VN

Atherogenicity of blood serum from patients with coronary heart disease

Author(s): Chazov EI, Tertov VV, Orekhov AN, Lyakishev AA, Perova NV, et al.

Antiatherosclerotic effects of calcium antagonists

Author(s): Orekhov AN, Baldenkov GN, Tertov VV, Ruda MYa, Khashimov KA, et al.

Effects of garlic on atherosclerosis

Author(s): Orekhov AN, Grünwald J

Anti-atherosclerotic therapy based on botanicals

Author(s): Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, et al.

The antiatherosclerotic effect of Allium sativum

Author(s): Koscielny J, Klüssendorf D, Latza R, Schmitt R, Radtke H, et al.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) Am J Cardiol 75: 455-459

Author(s): Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, et al.

Kuopio Atherosclerosis Prevention Study (KAPS)

Author(s): Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, et al.

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events

Author(s): Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, et al.

Beneficial effects of colestipol-niacin therapy on the common carotid artery

Author(s): Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, et al.

Coronary angiographic changes with lovastatin therapy

Author(s): Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, et al.

Carotid plaque morphologic characteristics

Author(s): Aidinian G, Weiswasser JM, Arora S, Abularrage CJ, Singh N, et al.

Thematic review series: The immune system and atherogenesis

Author(s): Daugherty A, Webb NR, Rateri DL, King VL

Evidence-based assessment of the impact of the WHI on women's health

Author(s): Burger HG, MacLennan AH, Huang KE, Castelo-Branco C